Brighthouse Financial, Inc. (BHF)
NASDAQ: BHF · Real-Time Price · USD
46.45
+0.31 (0.67%)
Aug 13, 2025, 9:49 AM - Market open
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Revance Therapeutics stock have a consensus rating of "Hold" and an average price target of $56.44, which forecasts a 21.51% increase in the stock price over the next year. The lowest target is $42 and the highest is $72.
Price Target: $56.44 (+21.51%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 6 | 6 | 6 | 6 | 6 | 5 |
Sell | 1 | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 9 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Keefe, Bruyette & Woods | Keefe, Bruyette & Woods | Hold Maintains $57 → $50 | Hold | Maintains | $57 → $50 | +7.64% | Aug 11, 2025 |
Barclays | Barclays | Buy Maintains $70 → $65 | Buy | Maintains | $70 → $65 | +39.94% | Aug 8, 2025 |
Morgan Stanley | Morgan Stanley | Sell Maintains $45 → $42 | Sell | Maintains | $45 → $42 | -9.58% | Jul 14, 2025 |
Wells Fargo | Wells Fargo | Hold Maintains $53 → $54 | Hold | Maintains | $53 → $54 | +16.25% | Jul 10, 2025 |
JP Morgan | JP Morgan | Sell Maintains $56 → $63 | Sell | Maintains | $56 → $63 | +35.63% | Jul 8, 2025 |
Financial Forecast
Revenue This Year
8.93B
from 6.30B
Increased by 41.89%
Revenue Next Year
9.20B
from 8.93B
Increased by 2.98%
EPS This Year
18.96
from 4.64
Increased by 308.59%
EPS Next Year
21.90
from 18.96
Increased by 15.49%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 9.5B | 9.9B | 10.2B | |
Avg | 8.9B | 9.2B | 9.3B | |
Low | 8.5B | 8.6B | 8.6B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 50.5% | 11.2% | 10.6% | |
Avg | 41.9% | 3.0% | 1.6% | |
Low | 35.3% | -3.3% | -6.3% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 20.53 | 24.96 | 27.83 | |
Avg | 18.96 | 21.90 | 24.24 | |
Low | 17.61 | 19.60 | 21.34 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 342.4% | 31.6% | 27.1% | |
Avg | 308.6% | 15.5% | 10.7% | |
Low | 279.5% | 3.4% | -2.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.